SCHEMBL31395484

SCHEMBL31395484

Fc1ccc(Nc2ncccc2Br)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.58
GRM4 Q14833 1/20 0.53
MAPT P10636 4/20 0.46
KDR P35968 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KCNH3 Q9ULD8 2/20 0.44
AURKA O14965 1/20 0.44
MAPK1 P28482 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279335 0.83 DHODH (0.56) DHODHGRM4MAPTRAB9AMAPK1
SCHEMBL30114249 0.81 EPHX2 (0.56) DHODHRAB9ACYP1A2CYP3A4TDP1
SCHEMBL24879902 0.81 EPHX2 (0.56) DHODHRAB9ACYP1A2CYP3A4TDP1
SCHEMBL25339954 0.81 PIP4K2A (0.44) DHODHGRM4MAPTNPC1RAB9A
SCHEMBL30519327 0.81 PIP4K2A (0.44) DHODHGRM4MAPTNPC1RAB9A
SCHEMBL11398989 0.79 CA12 (0.62) DHODHGRM4MAPTKDRNPC1
SCHEMBL14818781 0.79 RAB9A (0.63) DHODHGRM4MAPTKDRNPC1
SCHEMBL2041513 0.78 DHODH (0.56) DHODHGRM4MAPTKDRNPC1
SCHEMBL23319512 0.78 ABCG2 (0.50) DHODHKDRNPC1RAB9AKDM4E
SCHEMBL20406647 0.78 TRPV1 (0.48) CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 EP disclosed
WO-2025010291-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY THE GENERAL HOSPITAL CORPORATION (US) 2025-01-09 WO disclosed